Cargando…

Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study

BACKGROUND: The purpose of this retrospective study was to evaluate the survival outcomes of pembrolizumab (PEM) plus enzalutamide (ENZ) versus PEM alone in selected populations of men with previously untreated metastatic castration-resistant prostate cancer (mCRPC) harbouring programmed cell death...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Huanyi, Liu, Qilong, Zeng, Xianshang, Yu, Weiguang, Xu, Guixing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045189/ https://www.ncbi.nlm.nih.gov/pubmed/33849473 http://dx.doi.org/10.1186/s12885-021-08156-1

Ejemplares similares

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

Uncemented versus cemented arthroplasty after metal-on-metal total hip replacement in patients with femoral neck fractures: a retrospective study
por: Liu, Wenlu, et al.
Publicado: (2021)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Dual-Mobility Cup Total Hip Arthroplasty for Displaced Femoral Neck Fractures: A Retrospective Study With a Median Follow-Up of 5 Years
por: Zhang, Zhenfa, et al.
Publicado: (2021)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America
por: Joshua, Anthony M., et al.
Publicado: (2015)

Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel
por: Armstrong, Andrew J., et al.
Publicado: (2017)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)

Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
por: Gibbons, Jacqueline A.
Publicado: (2015)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
por: Alibhai, Shabbir M. H., et al.
Publicado: (2021)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
por: Bui, Cat N., et al.
Publicado: (2016)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab)
por: Peiffer, Lauren B., et al.
Publicado: (2022)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients
por: Kim, Choung-Soo, et al.
Publicado: (2016)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Association of dyslipidemia with chronic non-malignant pain in elderly patients with femoral neck fractures treated by primary total hip arthroplasty: a retrospective study
por: Wang, Chen, et al.
Publicado: (2021)

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
por: Luo, Jia, et al.
Publicado: (2016)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
por: Pu, Yeong-Shiau, et al.
Publicado: (2022)

Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide
por: Zedan, A. H., et al.
Publicado: (2023)

Treatment of 2-Part Proximal Humeral Fractures in Osteoporotic Patients With Medial Calcar Instability Using a PHILOS Plate Plus an Allogeneic Fibula Inserted Obliquely – A Retrospective Study
por: Cheng, Huihui, et al.
Publicado: (2021)

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
por: Tsao, Phoebe A., et al.
Publicado: (2023)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients
por: Hsieh, Yu-Ting, et al.
Publicado: (2021)

Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan
por: Okumura, Hiroyuki, et al.
Publicado: (2021)

A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE
por: Payne, Heather, et al.
Publicado: (2021)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2i166dfn6j19fcp0fj5vovc531